Staff Reports
Good news in medicine doesn’t always come wrapped in miracles. This week an experimental drug called bepirovirsen — nicknamed “bepi” and developed by GSK with Ionis — showed in trials that some people with chronic hepatitis B can stop all treatment and still keep the virus under control. The results were presented in Barcelona and published in the New England Journal of Medicine, and the drug is now under fast-track review by the FDA with a decision expected in October.
What the trials actually showed
The studies enrolled about 1,838 patients who got weekly bepi shots for six months on top of their regular hepatitis B pills. If their virus stayed undetectable for six months after stopping the shots, they could stop the pills too. About 1 in 5 people given bepi reached that “functional cure” — meaning the virus stayed low enough for the immune system to keep it in check. No patients who got the dummy shots achieved that result.
How the drug works — and who it helped
Bepirovirsen works by binding to the virus’s genetic material, cutting down viral replication and lowering levels of the surface “S” protein that helps hepatitis B hide. That seems to let the immune system take over. Patients who started with lower S protein levels did a bit better, and the trials did not include people with cirrhosis or very high S protein. So this helps a slice of patients — an important slice, but not everyone.
Safety, the FDA sprint, and practical questions
Side effects reported were mostly mild — injection site redness or pain and some temporary rises in liver enzymes. That said, longer follow-up is still needed. GSK has tracked a small group for up to three years and most are still doing well, but large, diverse, long-term data matter. The fast-track FDA review and reviews in Europe, Japan and China mean regulators will have to balance urgent need with careful checks. And yes, we should expect questions about price, access, and who gets priority when a new medicine like this comes to market.
So be cautiously optimistic. A functional cure for some hepatitis B patients would be real progress after decades of only lifelong pills. But this is not a universal cure, and it highlights the gap between scientific advances and real-world access. Policymakers and companies should push for affordable, global access and keep supporting prevention — including widespread vaccination — while we let the data and regulators do their work. If we do that, bepi could become more than a headline; it could be a public-health win that actually helps people who need it most.
